Yosef Maruvka
Assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Year:
2026
The rapid increase in available genome assemblies allows eukaryote-wide analyses of mutation rates and mutational spectra, yet whole-genome alignment remains a major computational bottleneck. We present CORAL, a scalable framework for inferring branch-specific substitutions without a centralized whole-genome alignment. CORAL fragments sister genomes into pseudo-reads, aligns them to an outgroup, and assigns substitutions by parsimony. CORAL achieved high concordance with three independent resources for both mutation rates and 96-category spectra. Applying CORAL to 5,090 species with calibrated divergence times, we generated the largest comparative atlas of mutation rates and spectra across animals, plants, fungi, and protists. Mutation rates vary by orders of magnitude and correlate with life-history traits such as lifespan and body weight. We find that mutation spectra are major determinants of each clade’s genomic trinucleotide composition and exhibit strong phylogenetic structure. We identified seven evolutionary mutational signatures, including two novel signatures and three previously observed only in cancer. Signature activities varied widely, and for several processes, tracked life-history covariates, suggesting distinct etiologies. Together, CORAL and this extensive atlas establish a powerful framework for comparative genomics, overcoming alignment bottlenecks to reveal the forces driving molecular evolution.
Year:
2026
Pathological complete remission in metastatic colorectal adenocarcinoma. (A) Baseline (hematoxylin-eosin, CD8 and PD-L1). (B) Post-nivolumab: no detectable tumor cells, increased inflammation, and increase in CD8 and PD-L1 expression. All IHC images are 100X.
Year:
2025
Pathological complete remission in metastatic colorectal adenocarcinoma. (A) Baseline (hematoxylin-eosin, CD8 and PD-L1). (B) Post-nivolumab: no detectable tumor cells, increased inflammation, and increase in CD8 and PD-L1 expression. All IHC images are 100X.
Year:
2024
Pathological complete remission in metastatic colorectal adenocarcinoma. (A) Baseline (hematoxylin-eosin, CD8 and PD-L1). (B) Post-nivolumab: no detectable tumor cells, increased inflammation, and increase in CD8 and PD-L1 expression. All IHC images are 100X.
Year:
2024
Purpose: Checkpoint-inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory non-hematological cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch-repair deficiency (MMRD). Patients and methods: Twenty patients were screened, and ten ultimately included in the response cohort of whom nine had TMB >10mut/Mb (three initially eligible based on MMRD) and one patient had TMB between 5-10 mut/Mb. Results: Delayed immune responses contributed to best overall response of 50%, improving on initial objective responses (20%) and leading to 2-year overall survival (OS) of 50% (95% CI; 27, 93). Four children, including three with refractory malignant gliomas are in complete remission at a median follow-up of 37-months (range: 32.4-60), culminating in 2-year OS of 43% (95% CI; 18.2, 100). Biomarker analyses confirmed benefit in children with germline MMRD, microsatellite instability, higher activated and lower regulatory circulating T-cells. Stochastic mutation accumulation driven by underlying germline MMRD impacted the tumor microenvironment, contributing to delayed responses. No benefit was observed in the single patient with a MMR-proficient tumour and TMB 7.4 mut/Mb. Conclusions: Nivolumab resulted in durable responses and prolonged survival for the first time in a pediatric trial of refractory hypermutated cancers including malignant gliomas. Novel biomarkers identified here need to be translated rapidly to clinical care to identify children who can benefit from checkpoint-inhibitors, including for upfront management of their cancers.
Year:
2024
Genomic features of patients with RRD-HGG treated with salvage therapies ( n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).
Year:
2024
Immune checkpoint inhibition (ICI) is effective for replication-repair-deficient, high-grade gliomas (RRD-HGG). The clinical/biological impact of immune-directed approaches after failing ICI monotherapy is unknown. We performed an international study on 75 patients treated with anti–PD-1; 20 are progression free (median follow-up, 3.7 years). After second progression/recurrence ( n = 55), continuing ICI-based salvage prolonged survival to 11.6 months ( n = 38; P P = 0.03). Delayed, sustained responses were observed, associated with changes in mutational spectra and the immune microenvironment. Response to reirradiation was explained by an absence of deleterious postradiation indel signatures (ID8). CTLA4 expression increased over time, and subsequent CTLA4 inhibition resulted in response/stable disease in 75%. RAS–MAPK-pathway inhibition led to the reinvigoration of peripheral immune and radiologic responses. Local (flare) and systemic immune adverse events were frequent (biallelic mismatch-repair deficiency > Lynch syndrome). We provide a mechanistic rationale for the sustained benefit in RRD-HGG from immune-directed/synergistic salvage therapies. Future approaches need to be tailored to patient and tumor biology. Significance: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological and immune properties, which evolve over time. Future research should focus on combinatorial regimens that increase patient survival while limiting immune toxicity. This article is featured in Selected Articles from This Issue, p. 201
Year:
2024
Patients receiving dual-checkpoint inhibition with ipilimumab and anti–PD-1 after failing ICI monotherapy ( n = 24). A, Swimmer's plot for each patient, showing the best documented radiologic response at any time during treatment. Inset, representative radiologic image showing response to dual-checkpoint inhibition. B, Progression-free (PFS2) and overall survival (OS2). C, Normalized CTLA4 expression counts generated using NanoString platform (Methods) for in-house non-RRD, nonmalignant brain controls, and at different time points for RRD-HGG. D, Paired analysis of normalized CTLA4 expression counts before and after anti–PD-1 therapy for the same patient. E, Toxicities (≥CTCAE grade 3) observed in CMMRD and Lynch syndrome patients on dual ICI.
Year:
2024
Delayed response after initial progression on continued anti–PD-1 monotherapy. A, Delayed response after initial progression on nivolumab monotherapy. B, Cyst decompression and biopsy at progression showed a more mitotically active and higher grade tumor with higher TMB and increased CD8 T-cell infiltration. C, Mutation overlap showed minimal overlap of the somatic mutational spectrum between the two time points (200X magnification; scale bars represent 50 µm). D, Normalized expression counts of immune markers before initiation and after progression on anti–PD-1 monotherapy using the NanoString platform (100X magnification, scale bars represent 100 µm; Methods).
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (21)
Daniel A. Morgenstern
Royal Marsden NHS Foundation Trust
Ryuma Tanaka
Assistant Professor
Nationwide Children's Hospital
David Malkin
University of Toronto
Derek S. Tsang
Staff Radiation Oncologist
-
Uri Tabori
Section Head of Neuro-Oncology
Hospital for Sick Children
David Ziegler
Professor
University of New South Wales
Adam Shlien
Wellcome Sanger Institute
Rebecca Deyell
Clinical Associate Professor
The University of British Columbia
Pamela S. Ohashi
University of Toronto
Anita Villani
Hospital for Sick Children
Ute Bartels
University of Toronto
Kim Erika Nichols
Full Member
St. Jude Children's Research Hospital
Carl Koschmann
University of Michigan Medical School
Michal Zapotocky
University Hospital in Motol
Gad Getz
Broad Institute
Eric Bouffet
Neuro-Oncologist
Hospital for Sick Children
Birgit Ertl-Wagner
Radiologist-in-Chief
Hospital for Sick Children
Vijay Ramaswamy
Associate Professor
University of Toronto
Trevor J. Pugh
Professor
University Health Network
Anirban Das
Hospital for Sick Children
Peter B. Dirks
-
Make your next move.
Prepare your application
Review drafts before you send them.